BrainsWay (BWAY) Competitors

Iradimed (NASDAQ:IRMD) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, community ranking, institutional ownership and valuation.

Do insiders & institutionals believe in IRMD or BWAY?

92.3% of Iradimed shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 37.1% of Iradimed shares are owned by company insiders. Comparatively, 19.0% of BrainsWay shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer IRMD or BWAY?

In the previous week, Iradimed had 4 more articles in the media than BrainsWay. MarketBeat recorded 8 mentions for Iradimed and 4 mentions for BrainsWay. BrainsWay's average media sentiment score of 1.60 beat Iradimed's score of 1.45 indicating that BrainsWay is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iradimed	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BrainsWay	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has preferable earnings & valuation, IRMD or BWAY?

Iradimed has higher revenue and earnings than BrainsWay. Iradimed is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iradimed	$73.24M	9.02	$19.23M	$1.50	34.64
BrainsWay	$41.02M	3.84	-$4.20M	$0.17	49.12

Does the MarketBeat Community believe in IRMD or BWAY?

Iradimed received 189 more outperform votes than BrainsWay when rated by MarketBeat users. However, 67.31% of users gave BrainsWay an outperform vote while only 65.40% of users gave Iradimed an outperform vote.

Company	Underperform	Outperform
Iradimed	Outperform Votes 259 65.40%	Underperform Votes 137 34.60%
BrainsWay	Outperform Votes 70 67.31%	Underperform Votes 34 32.69%

Is IRMD or BWAY more profitable?

Iradimed has a net margin of 26.26% compared to BrainsWay's net margin of 3.88%. Iradimed's return on equity of 24.12% beat BrainsWay's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iradimed	26.26%	24.12%	21.20%
BrainsWay	3.88%	3.52%	2.26%

Which has more risk and volatility, IRMD or BWAY?

Iradimed has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Do analysts recommend IRMD or BWAY?

Iradimed currently has a consensus price target of $72.00, indicating a potential upside of 38.57%. BrainsWay has a consensus price target of $13.17, indicating a potential upside of 57.68%. Given BrainsWay's higher possible upside, analysts plainly believe BrainsWay is more favorable than Iradimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iradimed	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
BrainsWay	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Iradimed beats BrainsWay on 11 of the 17 factors compared between the two stocks.